DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS

NEWS RELEASE

Released: July 6, 2011

Defense Health Program
Department of Defense Breast Cancer Research Program
Funding Opportunities for Fiscal Year 2011 (FY11)

The Fiscal Year 2011 (FY11) Defense Appropriations Act provides $150 million to the Department of Defense Breast Cancer Research Program (BCRP) to support innovative, high-impact breast cancer research. The BCRP is administered by the US Army Medical Research and Materiel Command (USAMRMC) through the Office of Congressionally Directed Medical Research Programs (CDMRP).

The BCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY11 BCRP program announcements and general application instructions for the following award mechanisms are anticipated to be posted on Grants.gov in late July 2011.

Award Mechanism Eligibility Key Mechanism Elements Funding
Clinical Translational Research Award Investigators at or above the level of Assistant Professor (or equivalent)
  • Supports the acceleration of research with a high potential for direct clinical translation that will result in significant improvements over current approaches to breast cancer prevention and/or therapy.
  • Applications will be supported in two phases. Phase I will enable completion of preclinical translational studies and FDA approvals (if needed). Phase II will initiate and execute the clinical trial.
  • Preliminary data is required.
  • Preproposal is required; application submission is by invitation only.
  • Maximum funding of $12M for direct costs (plus indirect costs).
  • Period of performance not to exceed 5 years.
Impact Award Investigators at or above the level of Assistant Professor (or equivalent)
  • Supports unique research projects that focus on scientific and clinical breast cancer issues, which, if successfully addressed, could ultimately revolutionalize the understanding, prevention, and/or treatment of breast cancer.
  • Applications that focus on less explored or poorly understood areas that are of significant importance in breast cancer are strongly encouraged.
  • Preproposal is required; application submission is by invitation only.
  • Maximum funding of $2M for direct costs (plus indirect costs).
  • Period of performance not to exceed 5 years.

All applications must conform to the final program announcements and application instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all USAMRMC funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

A pre-application is required and must be submitted through the CDMRP eReceipt website (http://cdmrp.org) prior to the pre-application deadline. Applications must be submitted through the federal government's single-entry portal, Grants.gov. Requests for email notification of the program announcements release may be sent to help@cdmrp.org. For more information about the BCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil).

Point of Contact: